This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.
Read more
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress
ITM to Host Scientific Precision Oncology Symposium in Parallel to the ASCO Annual Meeting on Friday, June 03, 2022
ITM kündigt Symposium und Präsenz auf der 60. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig an
ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177
ITM Announces Successful Completion of Patient Recruitment for its Phase III Trial, COMPETE, with Lead Radiotherapeutic ITM-11 (n.c.a. lutetium-177-edotreotide)
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer
ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmaceuticals
ITM to Support Educational Symposium on Multi-disciplinary Approaches to Personalized Medicine at the 2022 SNMMI Therapeutics Conference
ITM Presents Design of Second Phase III Trial, COMPOSE, with Radiopharmaceutical ITM-11 for the Treatment of Neuroendocrine Tumors at Annual ENETS Conference 2022
Back to Press Releases